ATHEROSCLEROSIS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2143552, encodeId=4f0321435529e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c302384757, createdName=二院赵主任, createdTime=Sun Jun 18 22:43:49 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1233808, encodeId=8698123380836, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：纯基础，实验设计比较单薄，被导师要求必须投AS，内心也知道拒稿概率极大，先提供一些投稿时间上的数据。 Submitted到Editor assigned大约3天，With editor状态维持了大约4天，中途看到日期更新了1次之后很快到了Under review。在Tracking那个链接看到发出2+审稿人邀请，最开始只有1个同意审稿，还庆幸是不是只有1个审稿人，想多了最后还是2+。从投稿开始刚好1个月，All review completed，现在是Decision in process。 正在准备下一个杂志。希望导师在他下一个学生那里圆梦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=380e1627463, createdName=helenwu1990, createdTime=Thu Jul 21 12:07:37 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120925, encodeId=5565212092584, content=你, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:24:06 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120924, encodeId=d0d8212092403, content=请问这个杂志允许共同通讯作者吗（两位通讯作者）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:23:47 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106376, encodeId=a86921063e669, content=Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:01:25 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106375, encodeId=ca3421063e542, content=审稿速度:1.0 经验分享：Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:00:37 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100454, encodeId=9573210045418, content=偏重的研究方向：动脉粥样硬化;心血管;临床流行病学 经验分享：已经under review快两月啦还只有一个接受邀请。。。大家也这么慢嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b48100738, createdName=ms9000001152355498, createdTime=Mon Nov 14 17:26:33 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226129, encodeId=22241226129f2, content=20天才送外审审了20天还没回来的确有点偏慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Mon Jun 13 10:49:36 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549024, encodeId=37675490246c, content=麻烦问下这个杂志如果接收后需要提供完整的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc831640055, createdName=marwin, createdTime=Wed Nov 08 18:07:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229498, encodeId=da401229498cc, content=审稿一个月回来了想问下Revise de Novo是大修吗修回后接受几率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Jun 29 16:46:41 CST 2022, time=2022-06-29, status=1, ipAttribution=)]

2023-06-18 二院赵主任来自湖南省

审稿速度:6.0 | 投稿命中率:50.0
经验分享：1

46 0

[GetPortalCommentsPageByObjectIdResponse(id=2143552, encodeId=4f0321435529e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c302384757, createdName=二院赵主任, createdTime=Sun Jun 18 22:43:49 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1233808, encodeId=8698123380836, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：纯基础，实验设计比较单薄，被导师要求必须投AS，内心也知道拒稿概率极大，先提供一些投稿时间上的数据。 Submitted到Editor assigned大约3天，With editor状态维持了大约4天，中途看到日期更新了1次之后很快到了Under review。在Tracking那个链接看到发出2+审稿人邀请，最开始只有1个同意审稿，还庆幸是不是只有1个审稿人，想多了最后还是2+。从投稿开始刚好1个月，All review completed，现在是Decision in process。 正在准备下一个杂志。希望导师在他下一个学生那里圆梦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=380e1627463, createdName=helenwu1990, createdTime=Thu Jul 21 12:07:37 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120925, encodeId=5565212092584, content=你, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:24:06 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120924, encodeId=d0d8212092403, content=请问这个杂志允许共同通讯作者吗（两位通讯作者）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:23:47 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106376, encodeId=a86921063e669, content=Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:01:25 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106375, encodeId=ca3421063e542, content=审稿速度:1.0 经验分享：Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:00:37 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100454, encodeId=9573210045418, content=偏重的研究方向：动脉粥样硬化;心血管;临床流行病学 经验分享：已经under review快两月啦还只有一个接受邀请。。。大家也这么慢嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b48100738, createdName=ms9000001152355498, createdTime=Mon Nov 14 17:26:33 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226129, encodeId=22241226129f2, content=20天才送外审审了20天还没回来的确有点偏慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Mon Jun 13 10:49:36 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549024, encodeId=37675490246c, content=麻烦问下这个杂志如果接收后需要提供完整的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc831640055, createdName=marwin, createdTime=Wed Nov 08 18:07:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229498, encodeId=da401229498cc, content=审稿一个月回来了想问下Revise de Novo是大修吗修回后接受几率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Jun 29 16:46:41 CST 2022, time=2022-06-29, status=1, ipAttribution=)]

2022-07-21 helenwu1990

审稿速度:1.0 | 投稿命中率:25.0
经验分享：纯基础，实验设计比较单薄，被导师要求必须投AS，内心也知道拒稿概率极大，先提供一些投稿时间上的数据。
Submitted到Editor assigned大约3天，With editor状态维持了大约4天，中途看到日期更新了1次之后很快到了Under review。在Tracking那个链接看到发出2+审稿人邀请，最开始只有1个同意审稿，还庆幸是不是只有1个审稿人，想多了最后还是2+。从投稿开始刚好1个月，All review completed，现在是Decision in process。
正在准备下一个杂志。希望导师在他下一个学生那里圆梦。

19 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143552, encodeId=4f0321435529e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c302384757, createdName=二院赵主任, createdTime=Sun Jun 18 22:43:49 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1233808, encodeId=8698123380836, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：纯基础，实验设计比较单薄，被导师要求必须投AS，内心也知道拒稿概率极大，先提供一些投稿时间上的数据。 Submitted到Editor assigned大约3天，With editor状态维持了大约4天，中途看到日期更新了1次之后很快到了Under review。在Tracking那个链接看到发出2+审稿人邀请，最开始只有1个同意审稿，还庆幸是不是只有1个审稿人，想多了最后还是2+。从投稿开始刚好1个月，All review completed，现在是Decision in process。 正在准备下一个杂志。希望导师在他下一个学生那里圆梦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=380e1627463, createdName=helenwu1990, createdTime=Thu Jul 21 12:07:37 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120925, encodeId=5565212092584, content=你, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:24:06 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120924, encodeId=d0d8212092403, content=请问这个杂志允许共同通讯作者吗（两位通讯作者）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:23:47 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106376, encodeId=a86921063e669, content=Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:01:25 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106375, encodeId=ca3421063e542, content=审稿速度:1.0 经验分享：Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:00:37 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100454, encodeId=9573210045418, content=偏重的研究方向：动脉粥样硬化;心血管;临床流行病学 经验分享：已经under review快两月啦还只有一个接受邀请。。。大家也这么慢嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b48100738, createdName=ms9000001152355498, createdTime=Mon Nov 14 17:26:33 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226129, encodeId=22241226129f2, content=20天才送外审审了20天还没回来的确有点偏慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Mon Jun 13 10:49:36 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549024, encodeId=37675490246c, content=麻烦问下这个杂志如果接收后需要提供完整的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc831640055, createdName=marwin, createdTime=Wed Nov 08 18:07:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229498, encodeId=da401229498cc, content=审稿一个月回来了想问下Revise de Novo是大修吗修回后接受几率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Jun 29 16:46:41 CST 2022, time=2022-06-29, status=1, ipAttribution=)]

2023-03-21 ms8000001212711568 来自北京

你

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2143552, encodeId=4f0321435529e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c302384757, createdName=二院赵主任, createdTime=Sun Jun 18 22:43:49 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1233808, encodeId=8698123380836, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：纯基础，实验设计比较单薄，被导师要求必须投AS，内心也知道拒稿概率极大，先提供一些投稿时间上的数据。 Submitted到Editor assigned大约3天，With editor状态维持了大约4天，中途看到日期更新了1次之后很快到了Under review。在Tracking那个链接看到发出2+审稿人邀请，最开始只有1个同意审稿，还庆幸是不是只有1个审稿人，想多了最后还是2+。从投稿开始刚好1个月，All review completed，现在是Decision in process。 正在准备下一个杂志。希望导师在他下一个学生那里圆梦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=380e1627463, createdName=helenwu1990, createdTime=Thu Jul 21 12:07:37 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120925, encodeId=5565212092584, content=你, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:24:06 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120924, encodeId=d0d8212092403, content=请问这个杂志允许共同通讯作者吗（两位通讯作者）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:23:47 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106376, encodeId=a86921063e669, content=Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:01:25 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106375, encodeId=ca3421063e542, content=审稿速度:1.0 经验分享：Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:00:37 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100454, encodeId=9573210045418, content=偏重的研究方向：动脉粥样硬化;心血管;临床流行病学 经验分享：已经under review快两月啦还只有一个接受邀请。。。大家也这么慢嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b48100738, createdName=ms9000001152355498, createdTime=Mon Nov 14 17:26:33 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226129, encodeId=22241226129f2, content=20天才送外审审了20天还没回来的确有点偏慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Mon Jun 13 10:49:36 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549024, encodeId=37675490246c, content=麻烦问下这个杂志如果接收后需要提供完整的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc831640055, createdName=marwin, createdTime=Wed Nov 08 18:07:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229498, encodeId=da401229498cc, content=审稿一个月回来了想问下Revise de Novo是大修吗修回后接受几率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Jun 29 16:46:41 CST 2022, time=2022-06-29, status=1, ipAttribution=)]

2023-03-21 ms8000001212711568 来自北京

请问这个杂志允许共同通讯作者吗（两位通讯作者）

43 0

[GetPortalCommentsPageByObjectIdResponse(id=2143552, encodeId=4f0321435529e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c302384757, createdName=二院赵主任, createdTime=Sun Jun 18 22:43:49 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1233808, encodeId=8698123380836, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：纯基础，实验设计比较单薄，被导师要求必须投AS，内心也知道拒稿概率极大，先提供一些投稿时间上的数据。 Submitted到Editor assigned大约3天，With editor状态维持了大约4天，中途看到日期更新了1次之后很快到了Under review。在Tracking那个链接看到发出2+审稿人邀请，最开始只有1个同意审稿，还庆幸是不是只有1个审稿人，想多了最后还是2+。从投稿开始刚好1个月，All review completed，现在是Decision in process。 正在准备下一个杂志。希望导师在他下一个学生那里圆梦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=380e1627463, createdName=helenwu1990, createdTime=Thu Jul 21 12:07:37 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120925, encodeId=5565212092584, content=你, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:24:06 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120924, encodeId=d0d8212092403, content=请问这个杂志允许共同通讯作者吗（两位通讯作者）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:23:47 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106376, encodeId=a86921063e669, content=Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:01:25 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106375, encodeId=ca3421063e542, content=审稿速度:1.0 经验分享：Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:00:37 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100454, encodeId=9573210045418, content=偏重的研究方向：动脉粥样硬化;心血管;临床流行病学 经验分享：已经under review快两月啦还只有一个接受邀请。。。大家也这么慢嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b48100738, createdName=ms9000001152355498, createdTime=Mon Nov 14 17:26:33 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226129, encodeId=22241226129f2, content=20天才送外审审了20天还没回来的确有点偏慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Mon Jun 13 10:49:36 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549024, encodeId=37675490246c, content=麻烦问下这个杂志如果接收后需要提供完整的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc831640055, createdName=marwin, createdTime=Wed Nov 08 18:07:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229498, encodeId=da401229498cc, content=审稿一个月回来了想问下Revise de Novo是大修吗修回后接受几率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Jun 29 16:46:41 CST 2022, time=2022-06-29, status=1, ipAttribution=)]

2022-12-16 遇事不决胺碘酮来自江苏省

Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022

52 0

[GetPortalCommentsPageByObjectIdResponse(id=2143552, encodeId=4f0321435529e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c302384757, createdName=二院赵主任, createdTime=Sun Jun 18 22:43:49 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1233808, encodeId=8698123380836, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：纯基础，实验设计比较单薄，被导师要求必须投AS，内心也知道拒稿概率极大，先提供一些投稿时间上的数据。 Submitted到Editor assigned大约3天，With editor状态维持了大约4天，中途看到日期更新了1次之后很快到了Under review。在Tracking那个链接看到发出2+审稿人邀请，最开始只有1个同意审稿，还庆幸是不是只有1个审稿人，想多了最后还是2+。从投稿开始刚好1个月，All review completed，现在是Decision in process。 正在准备下一个杂志。希望导师在他下一个学生那里圆梦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=380e1627463, createdName=helenwu1990, createdTime=Thu Jul 21 12:07:37 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120925, encodeId=5565212092584, content=你, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:24:06 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120924, encodeId=d0d8212092403, content=请问这个杂志允许共同通讯作者吗（两位通讯作者）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:23:47 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106376, encodeId=a86921063e669, content=Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:01:25 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106375, encodeId=ca3421063e542, content=审稿速度:1.0 经验分享：Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:00:37 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100454, encodeId=9573210045418, content=偏重的研究方向：动脉粥样硬化;心血管;临床流行病学 经验分享：已经under review快两月啦还只有一个接受邀请。。。大家也这么慢嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b48100738, createdName=ms9000001152355498, createdTime=Mon Nov 14 17:26:33 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226129, encodeId=22241226129f2, content=20天才送外审审了20天还没回来的确有点偏慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Mon Jun 13 10:49:36 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549024, encodeId=37675490246c, content=麻烦问下这个杂志如果接收后需要提供完整的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc831640055, createdName=marwin, createdTime=Wed Nov 08 18:07:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229498, encodeId=da401229498cc, content=审稿一个月回来了想问下Revise de Novo是大修吗修回后接受几率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Jun 29 16:46:41 CST 2022, time=2022-06-29, status=1, ipAttribution=)]

2022-12-16 遇事不决胺碘酮来自江苏省

审稿速度:1.0
经验分享：Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022

65 0

[GetPortalCommentsPageByObjectIdResponse(id=2143552, encodeId=4f0321435529e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c302384757, createdName=二院赵主任, createdTime=Sun Jun 18 22:43:49 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1233808, encodeId=8698123380836, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：纯基础，实验设计比较单薄，被导师要求必须投AS，内心也知道拒稿概率极大，先提供一些投稿时间上的数据。 Submitted到Editor assigned大约3天，With editor状态维持了大约4天，中途看到日期更新了1次之后很快到了Under review。在Tracking那个链接看到发出2+审稿人邀请，最开始只有1个同意审稿，还庆幸是不是只有1个审稿人，想多了最后还是2+。从投稿开始刚好1个月，All review completed，现在是Decision in process。 正在准备下一个杂志。希望导师在他下一个学生那里圆梦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=380e1627463, createdName=helenwu1990, createdTime=Thu Jul 21 12:07:37 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120925, encodeId=5565212092584, content=你, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:24:06 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120924, encodeId=d0d8212092403, content=请问这个杂志允许共同通讯作者吗（两位通讯作者）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:23:47 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106376, encodeId=a86921063e669, content=Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:01:25 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106375, encodeId=ca3421063e542, content=审稿速度:1.0 经验分享：Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:00:37 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100454, encodeId=9573210045418, content=偏重的研究方向：动脉粥样硬化;心血管;临床流行病学 经验分享：已经under review快两月啦还只有一个接受邀请。。。大家也这么慢嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b48100738, createdName=ms9000001152355498, createdTime=Mon Nov 14 17:26:33 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226129, encodeId=22241226129f2, content=20天才送外审审了20天还没回来的确有点偏慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Mon Jun 13 10:49:36 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549024, encodeId=37675490246c, content=麻烦问下这个杂志如果接收后需要提供完整的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc831640055, createdName=marwin, createdTime=Wed Nov 08 18:07:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229498, encodeId=da401229498cc, content=审稿一个月回来了想问下Revise de Novo是大修吗修回后接受几率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Jun 29 16:46:41 CST 2022, time=2022-06-29, status=1, ipAttribution=)]

2022-11-14 ms9000001152355498

偏重的研究方向：动脉粥样硬化;心血管;临床流行病学
经验分享：已经under review快两月啦还只有一个接受邀请。。。大家也这么慢嘛

1 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143552, encodeId=4f0321435529e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c302384757, createdName=二院赵主任, createdTime=Sun Jun 18 22:43:49 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1233808, encodeId=8698123380836, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：纯基础，实验设计比较单薄，被导师要求必须投AS，内心也知道拒稿概率极大，先提供一些投稿时间上的数据。 Submitted到Editor assigned大约3天，With editor状态维持了大约4天，中途看到日期更新了1次之后很快到了Under review。在Tracking那个链接看到发出2+审稿人邀请，最开始只有1个同意审稿，还庆幸是不是只有1个审稿人，想多了最后还是2+。从投稿开始刚好1个月，All review completed，现在是Decision in process。 正在准备下一个杂志。希望导师在他下一个学生那里圆梦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=380e1627463, createdName=helenwu1990, createdTime=Thu Jul 21 12:07:37 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120925, encodeId=5565212092584, content=你, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:24:06 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120924, encodeId=d0d8212092403, content=请问这个杂志允许共同通讯作者吗（两位通讯作者）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:23:47 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106376, encodeId=a86921063e669, content=Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:01:25 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106375, encodeId=ca3421063e542, content=审稿速度:1.0 经验分享：Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:00:37 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100454, encodeId=9573210045418, content=偏重的研究方向：动脉粥样硬化;心血管;临床流行病学 经验分享：已经under review快两月啦还只有一个接受邀请。。。大家也这么慢嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b48100738, createdName=ms9000001152355498, createdTime=Mon Nov 14 17:26:33 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226129, encodeId=22241226129f2, content=20天才送外审审了20天还没回来的确有点偏慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Mon Jun 13 10:49:36 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549024, encodeId=37675490246c, content=麻烦问下这个杂志如果接收后需要提供完整的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc831640055, createdName=marwin, createdTime=Wed Nov 08 18:07:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229498, encodeId=da401229498cc, content=审稿一个月回来了想问下Revise de Novo是大修吗修回后接受几率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Jun 29 16:46:41 CST 2022, time=2022-06-29, status=1, ipAttribution=)]

2022-06-13 zwjxyzcl

20天才送外审审了20天还没回来的确有点偏慢

146 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143552, encodeId=4f0321435529e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c302384757, createdName=二院赵主任, createdTime=Sun Jun 18 22:43:49 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1233808, encodeId=8698123380836, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：纯基础，实验设计比较单薄，被导师要求必须投AS，内心也知道拒稿概率极大，先提供一些投稿时间上的数据。 Submitted到Editor assigned大约3天，With editor状态维持了大约4天，中途看到日期更新了1次之后很快到了Under review。在Tracking那个链接看到发出2+审稿人邀请，最开始只有1个同意审稿，还庆幸是不是只有1个审稿人，想多了最后还是2+。从投稿开始刚好1个月，All review completed，现在是Decision in process。 正在准备下一个杂志。希望导师在他下一个学生那里圆梦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=380e1627463, createdName=helenwu1990, createdTime=Thu Jul 21 12:07:37 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120925, encodeId=5565212092584, content=你, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:24:06 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120924, encodeId=d0d8212092403, content=请问这个杂志允许共同通讯作者吗（两位通讯作者）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:23:47 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106376, encodeId=a86921063e669, content=Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:01:25 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106375, encodeId=ca3421063e542, content=审稿速度:1.0 经验分享：Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:00:37 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100454, encodeId=9573210045418, content=偏重的研究方向：动脉粥样硬化;心血管;临床流行病学 经验分享：已经under review快两月啦还只有一个接受邀请。。。大家也这么慢嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b48100738, createdName=ms9000001152355498, createdTime=Mon Nov 14 17:26:33 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226129, encodeId=22241226129f2, content=20天才送外审审了20天还没回来的确有点偏慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Mon Jun 13 10:49:36 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549024, encodeId=37675490246c, content=麻烦问下这个杂志如果接收后需要提供完整的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc831640055, createdName=marwin, createdTime=Wed Nov 08 18:07:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229498, encodeId=da401229498cc, content=审稿一个月回来了想问下Revise de Novo是大修吗修回后接受几率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Jun 29 16:46:41 CST 2022, time=2022-06-29, status=1, ipAttribution=)]

2017-11-08 marwin

麻烦问下这个杂志如果接收后需要提供完整的原始数据吗

341 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143552, encodeId=4f0321435529e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c302384757, createdName=二院赵主任, createdTime=Sun Jun 18 22:43:49 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1233808, encodeId=8698123380836, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：纯基础，实验设计比较单薄，被导师要求必须投AS，内心也知道拒稿概率极大，先提供一些投稿时间上的数据。 Submitted到Editor assigned大约3天，With editor状态维持了大约4天，中途看到日期更新了1次之后很快到了Under review。在Tracking那个链接看到发出2+审稿人邀请，最开始只有1个同意审稿，还庆幸是不是只有1个审稿人，想多了最后还是2+。从投稿开始刚好1个月，All review completed，现在是Decision in process。 正在准备下一个杂志。希望导师在他下一个学生那里圆梦。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=380e1627463, createdName=helenwu1990, createdTime=Thu Jul 21 12:07:37 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120925, encodeId=5565212092584, content=你, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:24:06 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120924, encodeId=d0d8212092403, content=请问这个杂志允许共同通讯作者吗（两位通讯作者）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fb5638881, createdName=ms8000001212711568, createdTime=Tue Mar 21 23:23:47 CST 2023, time=2023-03-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106376, encodeId=a86921063e669, content=Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:01:25 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106375, encodeId=ca3421063e542, content=审稿速度:1.0 经验分享：Received at Editorial Office 5 May 2022 Article revised 12 Nov 2022 Article accepted for publication 13 Dec 2022, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=遇事不决胺碘酮, createdTime=Fri Dec 16 20:00:37 CST 2022, time=2022-12-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100454, encodeId=9573210045418, content=偏重的研究方向：动脉粥样硬化;心血管;临床流行病学 经验分享：已经under review快两月啦还只有一个接受邀请。。。大家也这么慢嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b48100738, createdName=ms9000001152355498, createdTime=Mon Nov 14 17:26:33 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226129, encodeId=22241226129f2, content=20天才送外审审了20天还没回来的确有点偏慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Mon Jun 13 10:49:36 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549024, encodeId=37675490246c, content=麻烦问下这个杂志如果接收后需要提供完整的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc831640055, createdName=marwin, createdTime=Wed Nov 08 18:07:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229498, encodeId=da401229498cc, content=审稿一个月回来了想问下Revise de Novo是大修吗修回后接受几率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Jun 29 16:46:41 CST 2022, time=2022-06-29, status=1, ipAttribution=)]

2022-06-29 zwjxyzcl

审稿一个月回来了想问下Revise de Novo是大修吗修回后接受几率大不大

66 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务